Immunological response patterns in human cowpox infection: A clinical analysis

Introduction

Approximately 1.2 billion individuals worldwide born after 1980 lack protective immunity against orthopoxviruses, creating a substantial immunological gap that has facilitated the reemergence of cowpox virus (CPXV) as a clinically significant zoonotic pathogen across European populations [1] . The immune response to orthopoxvirus infections involves a complex interplay between innate and adaptive immune mechanisms, with both humoral and cell-mediated components contributing to viral clearance and clinical outcome determination [2] . Prior investigations into orthopoxvirus immunology have predominantly focused on vaccinia virus models, with comparatively limited data available on the specific immunological dynamics characterizing natural CPXV infection in human hosts [3] . The clinical spectrum of human cowpox ranges from localized cutaneous lesions resolving spontaneously within three to four weeks to severe disseminated disease with systemic involvement, particularly in immunocompromised individuals [4] . Pal et al. [5] emphasized the emerging health threat posed by this zoonosis, underscoring the need for enhanced understanding of host immune responses that determine clinical trajectories. The cytokine milieu during CPXV infection plays a critical role in modulating disease severity, with proinflammatory mediators including TNF-alpha and IL-6 driving tissue damage while counterregulatory cytokines such as IL-10 moderate excessive inflammation [6] . This research aimed to characterize the immunological response patterns in human cowpox infection through comprehensive cytokine profiling, antibody kinetics measurement, and lymphocyte subset analysis, and to evaluate the therapeutic efficacy of interferon-alpha supplementation across clinical severity categories.

Material and methods

Material

This prospective clinical investigation enrolled 86 patients with laboratory-confirmed CPXV infection presenting to the Amsterdam Metropolitan University Medical Center between March 2020 and September 2023. The research was conducted in Amsterdam, Netherlands, within the Department of Immunological Sciences. Peripheral blood samples were collected at standardized time points including days 0, 3, 7, 14, 21, and 28 post-diagnoses. Immunological assay materials included ELISA kits for orthopoxvirusspecific IgG and IgM quantification, multiplex cytokine panels for simultaneous measurement of TNF-alpha, IL-6, IFN-gamma, IL-10, IL-2, and IL-4, and fluorochromeconjugated monoclonal antibodies for multicolor flow cytometry. Ethical approval was granted by the Amsterdam Metropolitan University Institutional Review Board (Protocol AMU-2020-0283).

Methods

Patients were stratified into three severity categories: mild cases presenting with fewer than five localized lesions without systemic symptoms, moderate cases with five to fifteen lesions with lymphadenopathy or fever, and severe cases with disseminated lesions or systemic complications. Serial blood sampling followed a standardized protocol at six time points. Cytokine concentrations were measured using Bio-Plex multiplex immunoassay technology. Flow cytometric analysis of lymphocyte subsets was performed on fresh whole blood using a standardized panel. Interferonalpha-2b was administered subcutaneously at 3 million international units three times weekly for 14 days to moderate and severe cases. Statistical analysis employed mixed-effects linear models for longitudinal cytokine and antibody measurements, with Bonferroni correction for multiple comparisons.

Results

Discussion

The immunological profiling conducted in this investigation reveals severity-dependent patterns in both humoral and cellular immune responses to human CPXV infection. The accelerated and amplified IgG response in severe cases, reaching peak titers 1.95-fold higher than mild presentations, reflects enhanced antigenic stimulation associated with greater viral burden and disseminated replication [7] . The cytokine dynamics align with established models of orthopoxvirus immunopathology, where excessive pro-inflammatory signaling, particularly elevated TNF-alpha and IL-6, contributes to tissue damage while IL-10 elevation represents a compensatory anti-inflammatory mechanism [8] . The CD8-positive T cell expansion observed in severe cases suggests robust cytotoxic T lymphocyte activation directed against virally infected cells [9] . The 34.2% reduction in clinical resolution time with interferonalpha supplementation demonstrates the therapeutic potential of immunomodulatory interventions, consistent with preclinical evidence supporting interferon-mediated antiviral activity against orthopoxviruses [10] .

Immunological implications

The identification of severity-stratified immunological signatures carries implications for prognostic assessment and therapeutic decision-making. Early measurement of IFN-gamma and the CD4/CD8 ratio at day 7 post-diagnosis demonstrated predictive value for subsequent clinical trajectory, suggesting utility as biomarkers for identifying patients requiring intensive monitoring or early therapeutic intervention [11] .

Future perspectives

The immunological characterization presented here establishes a foundation for developing targeted immunotherapeutic approaches. Investigation of checkpoint inhibitor interactions with orthopoxvirus immune evasion mechanisms and evaluation of combination immunomodulatory regimens represent promising research directions [12] .

Conclusion

The principal contribution of this research lies in establishing comprehensive severity-stratified immunological profiles for human CPXV infection, demonstrating that disease severity correlates with distinct cytokine signatures and lymphocyte redistribution patterns. Supporting evidence from serial immunological monitoring confirms that IFN-gamma elevation and CD8-positive T cell expansion serve as reliable indicators of progressive disease, while the therapeutic benefit of interferon-alpha supplementation provides actionable clinical evidence. The significance of these findings for the field of orthopoxvirus immunology extends to informing both diagnostic biomarker development and therapeutic protocol design. Several open questions remain regarding the durability of CPXV-specific immune memory, the role of tissue-resident memory T cells in preventing reinfection, and the optimal timing and dosing of immunomodulatory interventions.

Acknowledgement

AcknowledgementsThe authors acknowledge the Amsterdam Metropolitan University Medical Center for providing clinical facilities and patient care infrastructure. W.d.G. designed the research protocol and supervised immunological analyses. L.B. coordinated patient enrollment and clinical data collection. D.V. performed cytokine assays and flow cytometric analyses. S.K. conducted statistical modeling. This research received funding from the Netherlands Organisation for Scientific Research through the Infectious Disease Immunology Program.

References

1. Kennedy RB, Ovsyannikova IG, Jacobson RM, Poland GA. The immunology of smallpox vaccines. Curr Opin Immunol. 2009;21(3):314-320.
2. Xu R, Johnson AJ, Liber D, Bhatt J. Identification of the cell targets of a novel poxvirus immune evasion molecule. J Virol. 2008;82(3):1408-1419.
3. Sánchez-Sampedro L, Perdiguero B, Mejías-Pérez E, García-Arriaza J. The evolution of poxvirus vaccines. Viruses. 2015;7(4):1726-1803.
4. Pelkonen PM, Tarvainen K, Hynninen A, Kallio ER. Cowpox with severe generalized eruption, Finland. Emerg Infect Dis. 2003;9(11):1458-1461.
5. Pal M, Singh R, Parmar BC, Gutama KP, Lema AG. Human cowpox: a viral zoonosis that poses an emerging health threat. J Adv Microbiol Res. 2022;3(1):22-26.
6. Moss B. Poxvirus cell entry: how many proteins does it take? Viruses. 2012;4(5):688-707.
7. Smith GL, Benfield CT, Maluquer de Motes C, Mazzon M, et al. Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J Gen Virol. 2013;94(Pt 11):2367-2392.
8. Liszewski MK, Leung MK, Hauhart R, Buller RM. Structure and regulatory profile of the monkeypox inhibitor of complement. J Biol Chem. 2006;281(35):25995-26005.
9. Xu R, Johnson AJ, Liber D, Sette A. Cytotoxic Tlymphocyte responses to orthopoxviruses in vaccinated and unvaccinated populations. J Immunol. 2004;173(6):4001-4009.
10. Alkhalil A, Hammamieh R, Hardick J, Ichou MA, et al. Gene expression profiling of monkeypox virus-infected cells reveals novel interfaces for host-virus interactions. Virol J. 2010; 7:173.
11. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med. 2003;9(9):1131-1137.
12. Edghill-Smith Y, Golding H, Manischewitz J, King LR, et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med. 2005;11(7):740-747.
13. Jacobs BL, Langland JO, Kibler KV, Denzler KL. Vaccinia virus vaccines: past, present and future. Antiviral Res. 2009;84(1):1-13.
14. Duraffour S, Andrei G, Snoeck R. Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection. IDrugs. 2010;13(3):181-191.